KIT as a therapeutic target in neuroendocrine prostate cancer
Details
Publication Year 2022-11-14,Volume 40,Issue #11,Page 1266-1268
Journal Title
Cancer Cell
Publication Type
Commentary
Abstract
Understanding lineage plasticity in prostate cancer cells is crucial to overcoming disease progression and therapeutic resistance. In this issue of Cancer Cell, Han et al. demonstrate that Foxa2 promotes luminal-to-neuroendocrine differentiation and that it also upregulates Kit expression in neuroendocrine cells. KIT signaling inhibition represents a promising therapeutic strategy in neuroendocrine prostate cancer.
Keywords
Male; Humans; *Prostatic Neoplasms/drug therapy/genetics/metabolism; *Carcinoma, Neuroendocrine/drug therapy/genetics; Signal Transduction; Cell Line, Tumor
Department(s)
Medical Oncology
PubMed ID
36332623
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 05:45:21
Last Modified: 2024-09-26 05:48:04

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙